Lung Cancer Pathophysiology: An Interdisciplinary Approach

Professor Nima Rezaei gained his medical degree (MD) from Tehran University of Medical Sciences and subsequently obtained an MSc in Molecular and Genetic Medicine and a PhD in Clinical Immunology and Human Genetics from the University of Sheffield, UK. He also spent a short-term fellowship of Pediatric Clinical Immunology and Bone Marrow Transplantation in the Newcastle General Hospital.  Professor Rezaei is now the Full Professor of Immunology and Vice Dean of Research and Technologies, School of Medicine, Tehran University of Medical Sciences, and the co-founder and Head of the Research Center for Immunodeficiencies. He is also the Founder of Universal Scientific Education and Research Network (USERN). Prof. Rezaei has already been the Director of more than two hundred research projects and has designed and participated in several international collaborative projects. Prof. Rezaei is the editor, editorial assistant, or editorial board member of more than fifty international journals. He has edited more than one hundred international books, has presented more than a thousand lectures/posters in congresses/meetings, and has published more than 1,500 scientific papers in the international journals.

• Interdisciplinary Approach in Lung Cancers.- Fundamental Elements of a High-Functioning Lung Cancer Multidisciplinary Team (MDT).- Epithelial to Mesenchymal Transition in Lung Cancer: When It Starts?.- Roles of Tumor Immune Microenvironment in Non-small Cell Lung Cancer.- Natural Killer Cells in Lung Cancer.- RNA-binding Proteins as a New Link Between COPD and Lung Cancer.- The Implication of miRNA Signature in the Characteristic Features and Diagnosis of Lung Cancer.- MicroRNAs in the Immunopathology and Treatment of Non-small Cell Lung Cancer.- Monitoring Exosomal Non-coding RNA in Lung Cancers.- Mediastinal Staging of Lung Cancer.- Pleural Mesothelioma: The Importance of Working Together.- Comprehensive Genomic Profiling in Lung Cancer in the Era of Immunotherapy Approaches: The Role of Molecular Tumour Boards.